Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine
• The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs
• Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers

Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific therapies. By matching treatments to the unique biology of a patient’s tumor, physicians can improve outcomes while reducing unnecessary exposure to therapies that may offer limited clinical benefit (https://nnw.fm/6iwro).

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is aligning its development strategy with this industry transformation through ONC010, its lead nanoparticle-encapsulated Polynucleotide kinase-phosphatase (“PNKP”) inhibitor. Designed for biomarker-selected cancers, ONC010 targets tumors that may be particularly susceptible to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at nnw.fm/ONNVF

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum.